Excellent performance verification of Vcheck Canine NT-proBNP (SCI journal)

A paper on the analytical validation of Vcheck Canine NT-proBNP (BIONOTE) has been published in the international journal, Veterinary Clinical Pathology (Science Citation Index, Impact factor 1.18).Paper: Analytical validation of a novel point-of-care immunoassay for canine N-terminal pro-brain natriuretic peptide analysis (Vet Clin Pathol. 2022;00:1–10.) See the attached document for the summary and click here for the full paper (open access).   This study aimed to analytically validate a Vcheck NT-proBNP assay according to American Society of Veterinary Clinical Pathology (ASVCP) and Clinical Laboratory Improvement Amendments (CLIA) specifications.   Precision Imprecision was considered acceptable with a coefficient of variation ranging from 9% at 4000 pmol/L to 20% at 600 pmol/L.   Accuracy Comparison of the Vcheck assay with the Cardiopet NT-proBNP assay revealed an excellent correlation with minimal bias (y=0.9x+37, R2=0.9) when preanalytical factors were controlled.   Preanalytical error Significant degradation of NT-proBNP occurred when current methods were used at refrigerated (average loss of 20%) and room temperatures (loss of at least 50%), which could change diagnostic and prognostic decision-making.   Interferents (analytical specificity) Spiking samples across the linear range of the assay with 35 mg/dL hemoglobin and 1000 mg/dL Intralipid did not reveal a statistically significant difference.   Reference intervals Age-partitioned reference intervals (95%) have upper reference limits of 750 pmol/L and 1280 pmol/L for 36 juvenile and 125 adult dogs, respectively.     According to this study, the Vcheck assay provides analytically acceptable results. Onsite testing can minimize variability related to preanalytical error and provide clinically useful contemporaneous results.   Also, the author emphasized that samples should be centrifuged immediately and analyzed within 2 hours of collection, due to significant degradation of NT-proBNP.   Results of this study demonstrate that the Vcheck NT-proBNP assay is a valid point-of-care cardiac biomarker using the canine serum.   Vcheck Canine NT-proBNP can be quantitatively measured using a fluorescent immunoassay analyzer (Vcheck) in a short time (15 minutes) and can be tested using a small amount of sample (serum 100 µl). Learn more

• 2022.04.07
• Hits : 11,671

BioNote USA, attending the Western Veterinary Conference which is the largest Veterinary Science Society in the United States

Bionote USA attended the Western Veterinary Conference to be held March 6th to March 9th, 2022 at the Mandalay Bay Convention Center in Las Vegas, Nevada.WVC’s Annual Conference is one of the largest, most influential gatherings of veterinary professionals in the world. Bionote USA communicated with veterinary workers and vets who attended the conference through participation in the booth about how Vcheck could develop and help veterinary medicine.   On this day, renowned Dr. Rozanski sponsored by Bionote, spoke about the role of NT-proBNP in clinical decision making and the benefits of point-of-care testing. NT-proBNP is correlated with heart size and systolic function, suggesting that the concentrations can be used to detect dogs with early disease. In addition, Vcheck Canine NT-proBNP is an in vitro diagnostic test kit for the quantitative measurement of NT-proBNP concentration in canine serum. This test kit precisely quantifies the degree of elevation in NT-proBNP levels in dogs. The ability to distinguish cardiac from non-cardiac causes of respiratory signs is important for further decisions on diagnostics and therapy. NT-proBNP allows distinguishing cardiac from respiratory disease in dogs with dyspnea. Also, this marker helps to detect dogs with Myxomatous Mitral Valve Degeneration (MMVD), which is the most common heart disease in dogs. In dogs with stable Congestive Heart Failure (CHF) due to MMVD, NT-proBNP is of value in monitoring the effectiveness of medical treatment for CHF. In large breeds, Dilated Cardiomyopathy (DCM) is the most common cause of heart disease. Annual screening tests are recommended to determine if DCM is present even if dogs at elevated risk are healthy. The measurement of NT-proBNP increases the diagnostic accuracy with Holter monitoring (91% accuracy). Vcheck Canine NT-proBNP: The one-step test procedure is easy to follow and provides fast results within 15 minutes using serum samples from dogs. Bionote USA completed the 2022 Western Veterinary Conference, and in addition, Bionote KOREA and Bionote CHINA also plan to hold various external activities and conferences. 

• 2022.03.14
• Hits : 4,613

BIONOTE.Inc won the prize of "National Tax Tower of 100 billion" on the occasion of the 56th Taxpayer's Day

  BIONOTE won the prize of "National Tax Tower of 100 billion" on March 3 in recognition of its contribution to national finances as an exemplary taxpayer on the occasion of the 56th Taxpayer's Day. The National Tax Tower of 100 billion is a monument in the name of the president, awarded to a high-value tax corporation with an annual total of more than 100 billion in corporate tax and special rural taxes voluntarily reported and paid by corporations since 2004. Bionote was awarded this time in recognition of its sincere tax payment, contribution to the community, and active contribution to society such as ethical business operation. Bionote CEO Cho Byung-ki said, "It is meaningful to contribute to the creation of a sincere tax culture, contributes to the healthy coexistence of people and animals, and will continue to contribute to the development of national finances through transparent management."

• 2022.03.07
• Hits : 4,960